Two components with separate contributions
Cytoreductive surgery removes visible peritoneal tumor. HIPEC circulates heated chemotherapy within the abdominal cavity during a defined treatment period. The contribution of surgery and the added benefit of HIPEC must be considered separately; the combination is not automatically superior for every cancer involving the peritoneum.
Separate the operation from the heated chemotherapy
Cytoreduction addresses visible deposits; heated chemotherapy treats the abdominal cavity during the operation. The specialist team considers the role of each component, the expected extent of surgery and how systemic treatment fits before or after the procedure.
Selection is the central decision
Primary tumor type, peritoneal disease burden, small-bowel involvement, disease elsewhere and the likelihood of complete cytoreduction matter. Nutritional state and the ability to tolerate a long operation are essential. Gastric, colorectal, appendiceal and ovarian cancers have different evidence and indications; findings cannot be transferred across them.
| Issue | Why it changes the plan |
|---|---|
| Primary cancer | Gastric, colorectal, appendiceal and ovarian evidence differs. |
| Extent and small-bowel involvement | May determine whether complete visible cytoreduction is possible. |
| Disease outside the abdomen | Can change the value of a local strategy. |
| Fitness and nutrition | Determine tolerance of surgery, recovery and subsequent treatment. |
Global treatment frontiers
International HIPEC research is refining patient selection, the completeness of cytoreduction and the contribution of heated chemotherapy for each cancer type. Gastric-cancer studies in Europe and China examine different regimens and clinical settings; HIPEC remains a specialist option whose role is assessed within the full treatment plan.
China’s HIPEC-09 protocol, published in 2026, asks a separate question: whether HIPEC after minimally invasive gastrectomy can prevent peritoneal metastasis in locally advanced disease. A prevention trial and treatment of established peritoneal spread are not the same indication. This is an active research direction, with patient selection more important than the appeal of the technology.
A substantial recovery commitment
The operation may involve several organ resections. Admission, nutrition, bowel recovery and rehabilitation can be prolonged. Ask about stoma risk, intensive-care needs, the center’s complication management and when systemic treatment can restart. A travel plan should leave room for an unpredictable recovery.
Ask what happens if the planned clearance is impossible
Imaging may underestimate peritoneal disease. Before surgery, discuss whether the team would stop, perform a limited procedure or pursue another plan if findings differ. Also discuss possible bowel resection, stoma, nutrition support and the time before systemic treatment can resume. These are central treatment choices, not minor consent details.
Risks that deserve explicit discussion
Leakage, bleeding, infection, thrombosis, kidney injury and marrow toxicity may occur. The chemotherapy drug and dose affect risk. A consultation should explain what happens if complete cytoreduction is impossible at surgery and how the team would change the plan.
Estimated total treatment cost
The estimated total cost of one cytoreductive operation with HIPEC and associated perioperative care is US$46,000–99,000. The extent of surgery and recovery needs are major cost factors.
What’s included
The total includes specialist and anesthesia assessment, necessary preoperative tests and imaging, cytoreductive surgery, anesthesia and operating-room services, HIPEC medicines and perfusion equipment, routine surgical consumables, pathology, necessary hospitalization and nursing, routine medicines, nutritional support, and early follow-up. Travel and accommodation are not included.
Your treatment plan
Multi-organ resection, reconstruction, complications or additional procedures may increase the cost. Separately arranged systemic anticancer treatment, later stoma reversal and long-term rehabilitation are assessed separately. Contact us for an estimate based on the proposed operation and care plan.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.